Liraglutide. GLP-1 receptor agonist treatment of type 2 diabetes treatment of obesity

Drugs of the Future

Volumn 33, Issue 1, 2008, Pages 13-20

  Gallwitz, B ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLIMEPIRIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN GLARGINE; LIRAGLUTIDE; METFORMIN; PLACEBO; ROSIGLITAZONE;

ADD ON THERAPY; ARTICLE; B LYMPHOCYTE; CELL FUNCTION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DISEASE ASSOCIATION; DRUG DOSE ESCALATION; DRUG EFFECT; ENZYME DEGRADATION; GLUCAGON RELEASE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; WEIGHT REDUCTION;

EID: 40949108971     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2008.033.01.1164951     Document Type: Article

References (44)

1. Smyth, S., Heron, A. Diabetes and obesity: The twin epidemics. Nat Med 2006, 12(1): 75-80.
2. Abuissa, H., Bel, D.S., O'Keefe, J.H. Jr. Strategies to prevent type 2 diabetes. Curr Med Res Opin 2005, 21(7): 1107-14.
3. Prentki, M., Nolan, C.J. Islet beta cell failure in type 2 diabetes. J Clin Invest 2006, 116(7): 1802-12.
4. Holst, J.J. Glucagon-like peptide-1: From extract to agent. The Claude Bernard Lecture 2005. Diabetologia 2006, 49(4): 253-60.
5. Taylor, R., Magnusson, I., Rothman, D.L., Cline, G.W., Caumo, A., Cobelli, C., Shulman, G.I. Direct assessment of liver glycogen storage by 13C nuclear magnetic resonance spectroscopy and regulation of glucose homeostasis after a mixed meal in normal subjects. J Clin Invest 1996, 97(1): 126-32.
6. Bogers, R.P., Bemelmans, W.J., Hoogenveen, R.T. et al. Association of overweight with increased risk of coronary heart disease partly independent of blood pressure and cholesterol levels: A meta-analysis of 21 cohort studies including more than 300 000 persons. Arch Intern Med 2007, 167(16): 1720-8.
7. Levetan, C. Oral antidiabetic agents in type 2 diabetes. Curr Med Res Opin 2007, 23(4): 945-52.
8. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998, 352(9131): 854-65.
9. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352(9131): 837-53.
10. Nathan, D.M., Buse, J.B., Davidson, M.B., Heine, R.J., Holman, R.R., Sherwin, R., Zinman, B. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006, 29(8): 1963-72.
11. Gallwitz, B. Exenatide in type 2 diabetes: Treatment effects in clinical studies and animal study data. Int J Clin Pract 2006, 60(12): 1654-61.
12. Buse, J.B., Henry, R.R., Han, J., Kim, D.D., Fineman, M.S., Baron, A.D. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004, 27(11): 2628-35.
13. DeFronzo, R.A., Ratner, R.E., Han, J., Kim, D.D., Fineman, M.S., Baron, A.D. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005, 28(5): 1092-100.
14. Kendall, D.M., Riddle, M.C., Rosenstock, J., Zhuang, D., Kim, D.D., Fineman, M.S., Baron, A.D. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005, 28(5): 1083-91.
15. Blonde, L., Klein, E.J., Han, J. et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 2006, 8(4): 436-47.
16. Drucker, D.J. The biology of incretin hormones. Cell Metab 2006, 3(3): 153-65.
17. Farilla, L., Bulotta, A., Hirshberg, B. et al. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 2003, 144(12): 5149-58.
18. Drucker, D.J., Nauck, M.A. The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006, 368(9548): 1696-705.
19. Agerso, H., Jensen, L.B., Elbrond, B., Rolan, P., Zdravkovic, M. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia 2003, 45(2): 195-202.
20. Rolin, B., Larsen, M.O., Gotfredsen, C.F., Deacon, C.F., Carr, R.D., Wilken, M., Knudsen, L.B. The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice. Am J Physiol Endocrinol Metab 2002, 283(4): E745-52.
21. Sturis, J., Gotfredsen, C.F., Romer, J. et al. GLP-1 derivative liraglutide in rats with beta-cell deficiencies: Influence of metabolic state on beta-cell mass dynamics. Br J Pharmacol 2003, 140(1): 123-32.
22. Bock, T., Pakkenberg, B., Buschard, K. The endocrine pancreas in non-diabetic rats after short-term and long-term treatment with the long-acting GLP-1 derivative NN2211. APMIS 2003, 111(12): 1117-24.
23. Larsen, P.J., Fledelius, C., Knudsen, L.B., Tang-Christensen, M. Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats. Diabetes 2001, 50(11): 2530-9.
24. Ribel, U., Larsen, M.O., Rolin, B. et al. NN2211: A long-acting glucagon-like peptide-1 derivative with antidiabetic effects in glucose-intolerant pigs. Eur J Pharmacol 202, 451(2): 217-25.
25. Damholt, B., Golor, G., Wierich, W., Pedersen, P., Ekblom, M, Zdravkovic, M. An open-label, parallel group study investigating the effects of age and gender on the pharmacokinetics of the once-daily glucagon-like peptide-1 analogue liraglutide. J Clin Pharmacol 2006, 46(6): 635-41.
26. Degn, K.B., Juhl, C.B., Sturis, J. et al. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes 2004, 53(5): 1187-94.
27. Madsbad, S., Schmitz, O., Ranstam, J., Jakobsen, G., Matthews, D.R. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): A 12-week, double-blind, randomized, controlled trial. Diabetes Care 2004, 27(6): 1335-42.
28. Feinglos, M.N., Saad, M.F., Pi-Sunyer, F.X., An, B., Santiago, O. Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with type 2 diabetes. Diabet Med 2005, 22(8): 1016-23.
29. Harder, H., Nielsen, L., Tu, D.T., Astrup, A. The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes. Diabetes Care 2004, 27(8): 1915-21.
30. Nauck, M.A., Hompesch, M., Filipczak, R., Le, T.D., Zdravkovic, M., Gumprecht, J. Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes. Exp Clin Endocrinol Diabetes 2006, 114(8): 417-23.
31. Vilsboll, T. Liraglutide: A once-daily GLP-1 analogue for the treatment of type 2 diabetes mellitus. Expert Opin Investig Drugs 2007, 16(2): 231-7.
32. Jacobsen, L.V., Hindsberger, C., Robson, R., Zdravkovic, M. Pharmacokinetics of the long-acting human GLP-1 analogue liraglutide in subjects with renal impairment. Diabetologia 2007, 50(Suppl. 1): S352.
33. Vilsboll, T., Zdravkovic, M., Le-Thi, T. et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care 2007, 30(6): 1608-10.
34. Mari, A., Degn, K., Brock, B., Rungby, J., Ferrannini, E., Schmitz, O. Effects of the long-acting human glucagon-like peptide-1 analog liraglutide on beta-cell function in normal living conditions. Diabetes Care 2007, 30(8): 2032-3.
35. Effect of liraglutide on blood glucose control in subjects with type 2 diabetes (LEAD 1) (NCT0031842). ClinicalTrials.gov Web site, December 19, 2007.
36. To compare the effect of liraglutide when given together with metformin with the effect of metformin given alone and with the effect of glimepiride and metformin given together (NCT00318461). ClinicalTrials.gov Web site, December 19, 2007.
37. To evaluate the effect of liraglutide versus glimepiride (Amaryl®) on haemoglobin A1c (NCT00294723). ClinicalTrials.gov Web site, December 19, 2007.
38. Effect of liraglutide on blood glucose control in subjects with type 2 diabetes (LEAD-4) (NCT00333151). ClinicalTrials.gov Web site, December 19, 2007.
39. Effect of liraglutide on blood glucose control in subjects with type 2 diabetes (LEAD-5) (NCT00331851). ClinicalTrials.gov Web site, December 19, 2007.
40. Liraglutide improves glucose control and lowers body weight in two phase 3 studies comprising more than 2,000 patients. Novo Nordisk Press Release, August 20, 2007.
41. Phase III study confirms that liraglutide treatment leads to both glucose and weight reduction with a low risk of hypoglycaemic events. Novo Nordisk Press Release, September 14, 2007.
42. Liraglutide provides significantly better glucose control than insulin glargine in phase 3 study. Novo Nordisk Press Release, June 21, 2007.
43. Final phase 3 study confirms very favourable effect of liraglutide on blood glucose control and body weight. Novo Nordisk Press Release, December 11, 2007.
44. Elbrond, B., Jakobsen, G., Larsen, S. et al. Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-3 dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects. Diabetes Care 2002, 25(8): 1398-404.